2021 Exhibitor List

2021 SABCS Onsite Exhibitors

Name Booth 
#ThisIsMBC Virtual
10x Genomics  906 & Virtual
Agendia, Inc     613 & Virtual
Agilent/Dako  729
Alamo Breast Cancer Foundation  1014
American Association for Cancer Research (AACR)  921 & Virtual
AstraZeneca  607
 529 & Virtual
Biotheranostics, A Hologic Company
 701 & Virtual
Caris Life Sciences    522
Coherus BioSciences     421 & Virtual
CSI Laboratories   823
Daiichi Sankyo  1027 & Virtual
Dignitana  821
Eisai, Inc   621 & Virtual
 Elsevier  T8
Elucent Medical  907 
Encore Medical Education, LLC  523
Endomag 625 
Epic Sciences  829 
Exact Sciences   401 & Virtual
Foundation Medicine, Inc   1025 & Virtual
Genentech  301 & Virtual
GE Healthcare    825, 922 & Virtual
Gilead Sciences
 429 & Virtual
Global Breast Cancer Conference    Virtual
Greenwich Lifesciences, Inc.   Virtual
Guardant Health  425
Harborside Press  T1
 Isoplexis T6 
 201, 207 & Virtual
Male Breast Cancer Coalition
MD Anderson Cancer Center  717 & Virtual
Menarini Silicon Biosystems  722
Menarini Stemline  1006
Merck & Co., Inc  629 & Virtual
METAvivor Research and Support, Inc
Myriad Genetics   1001
National Accreditation Program for Breast Center
Natera  723 & Virtual
NeoGenomics Laboratories  513 & Virtual
Novartis Oncology   612, 501, 407 & Virtual
OBI Pharma USA, Inc.
Olema Oncology  Virtual
The Oncologist  Virtual
Paxman USA Inc  406 & Virtual
 Pfizer Oncology
 311, 601 & Virtual
Pierre Fabre  Virtual
PrecisCa  T5
Predicine, Inc 720 
PreludeDx  915
Protean Biodiagnostics T4 
 Puma Biotechnology Virtual
Roche Information Solutions  1008
Sanofi Genzyme
 620 & Virtual
Seagen  507, 801, & Virtual
Seno Medical T3 
Silbiotech  715
Society of Surgical Oncology  1007
Spectrum Pharmaceuticals, Inc.
Stratpharma Switzerland
Survivingbreastcancer.org  T7
Tactile Medical  909
Tempus  807
Tersera Therapeutics Llc
Veracyte 521
Veru, Inc.  729
Viatris  307
Volpara Health 724
Xeos 423 
Zero Gravity  910

Product Theatre Schedule



Tuesday, December 7, 10:00 am

Cerianna: Seeing Deeper into Recurrent or Metastatic Breast Cancer
presented by GE Healthcare

Tuesday, December 7, 12:00 pm
 Explore data for an FDA-approved treatment option in HR+, HER2- breast cancer in certain adjuvant or metastatic settings.PP-AL-US-2989 © Lilly USA, LLC 2021. All rights reserved. 
presented by Lilly


Tuesday, December 7, 2:00 pm
Signatera for MRD detection in High-Risk Breast Cancer
presented by Natera

Tuesday, December 7, 4:00 pm 
Evolving the Paradigm of Care to Improve Outcomes for Women with ER+ Breast Cancer   
presented by Agendia

Wednesday, December 8, 10:00 am 
Considerations for Second-Line in HER2+ Metastatic Breast Cancer
presented by Daiichi Sankyo

Wednesday, December 8, 12:00 pm
TUKYSA® (tucatinib): Clinical Trial Data
presented by Seagen

Wednesday, December 8, 2:00 pm
Learn more about an FDA-approved treatment for mTNBC
presented by Gilead Sciences

Wednesday, December 8, 4:00 pm
Advancements in the Prevention of Chemotherapy-Induced Neutropenia: Understanding the Gap and its Managements
presented by BeyondSpring

Thursday, December 9, 10:00 am
Providing the Diagnostics You Need in Breast Cancer Care with One Lab
presented by Neogenomics

Thursday, December 9, 12:00 pm
The Evolving Role of the Oncotype DX® Test in Breast Cancer: TAILORx, RxPONDER, and Beyond
presented by Exact Sciences

Thursday, December 9, 2:00 pm
Clinical/Pathologic Features Are Unrelated to Benefit from Extended Endocrine: Breast Cancer Index is the modern tool for Selecting the right Patients
presented by Biotheranostics, A Hologic Company

Thursday, December 9, 4:00 pm
Resistance to Therapeutic Regimens in MBC: Translating Science to Clinical Decision-making
presented by Sanofi Genzyme

Friday, December 10, 10:00 am
A Treatment Option for Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
presented by Merck

Friday, December 10, 12:00 pm
Expert Perspectives on the Treatment of a Broad Range of Patients With HR+/HER2- Metastatic Breast Cancer
presented by Pfizer Oncology

Friday, December 10, 2:00 pm
A Comprehensive Solution: Somatic and Germline Testing with Artificial Intelligence Capabilities to Inform Treatment Options in Breast Cancer
presented by Tempus

Friday, December 10, 4:00 pm
Recent Developments in Predicting IO Response in TNBC and Other Cancers
presented by Oncocyte



9,572 Symposium attendees + 210 Media + 458 Exhibitors, Non-Exhibiting Sponsors & their Support Staff = 10,240 total attendance.  51% came from 102 countries outside the USA.  Click here to view an audited 2021 SABCS registration report, which includes further details.

Lead Retrieval

To request Lead Retrieval, log in to the Sponsorship Portal. Lead Retrieval is under the Sponsorship tab and select item in the drop-down menu. 

Code of Conduct

Exhibitors agree to adhere to the compliance guidelines and codes of conduct governing the interactions of drug and device manufacturers with healthcare professionals as promulgated by the U.S. Food and Drug Administration, the Department of Health and Human Services Office of the Inspector General, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Advanced Medical Technology Association AdvaMed.


  • Display elements and fixtures cannot exceed a height of ten feet (10’). This rule pertains to both in-line and island displays. 
  • An individual exhibit cannot straddle an aisle.
  • No microphones or vocal amplification may be used at any time.
  • Unstaffed exhibits are not permitted.
  • Sharing of booth space with an unrelated company is not permitted.  “Subleasing” of booth space to an unrelated company is not permitted.
  • Table exhibits: exhibit fixtures and product are limited to the table top only.
  • All ladders & related equipment must be removed from the building following move-in.
  • Departure and/or removal of exhibit prior to end of show will affect placement in subsequent years and may result in exhibitor being barred from exhibiting in the future.

Exhibit Schedule

Hours may be subject to change.

Exhibits open
Wednesday, December 7
10:00 AM – 5:00 PM
Thursday, December 8
10:00 AM – 5:00 PM
Friday, December 9
10:00 AM – 5:00 PM

Exhibitor Registration

Complimentary exhibit area only registrations entitle the registrant to access the virtual exhibit area only. Full registration is required in order to attend SABCS virtual programs.